Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 5 March 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 5 March 2026, 15:15 (CET) to 5 March 2026, 16:15 (CET)

Human medicines European public assessment report (EPAR): Otezla, apremilast, Date of authorisation: 15/01/2015, Revision: 25, Status: Authorised

List of European Union reference dates (EURD) and frequency of submission of periodic safety update reports (PSURs)

EMA/PE/0000230484

EMA/PE/0000227908

Opinion/decision on a Paediatric investigation plan (PIP): Voydeya, danicopan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: EMA/PE/0000227558

Opinion/decision on a Paediatric investigation plan (PIP): Zeftera (previously Zevtera), ceftobiprole medocaril (sodium), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: EMA/PE/0000227526

EMA/PE/0000227462

Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, efgartigimod alfa, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000227425